MedPath

Clinical pharmacology study of FYX-051 for subjects with renal insufficiency

Phase 2
Conditions
Subjects with renal insufficiency
Registration Number
JPRN-jRCT2080221510
Lead Sponsor
Fuji Yakuhin Co., Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
Male
Target Recruitment
Not specified
Inclusion Criteria

Subjects belonging to the following criteria of inulin clearance (Cin)
Normal group (Cin: 90mL/min/1.73m^2 or more),
Slightly-decreased group (Cin: 60mL/min/1.73m^2 or more, 90mL/min/1.73m^2 under),
Moderately-decreased group (Cin: 30mL/min/1.73m^2 or more, 60mL/min/1.73m^2 under),

Exclusion Criteria

Subject with disease of gut, heart and liver
Subject with surgical history of apparatus digestorius (gut, liver, gallbladder, bile duct, pancreas and so on) and kidney
Subject with AST(GOT) or ALT(GPT) of 100IU/L or more

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath